经动脉化疗栓塞的概况代表了肝细胞癌的介入治疗。
Landscape of transarterial chemoembolization represented interventional therapy for hepatocellular carcinoma.
作者信息
Fu Yang-Yang, Li Wen-Mao, Cai Hong-Qiao, Jiao Yan
机构信息
Department of The First Operation Room, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China.
Department of Rehabilitation, The Second Hospital of Jilin University, Changchun 130000, Jilin Province, China.
出版信息
World J Gastrointest Surg. 2024 Dec 27;16(12):3903-3906. doi: 10.4240/wjgs.v16.i12.3903.
Abstract
This article discusses the article written by Tan . Transarterial chemoembolization (TACE) is one of the main treatment methods for advanced hepatocellular carcinoma (HCC). There are other vascular interventional therapies, including drug-eluting bead TACE, transarterial radioembolization, and hepatic arterial infusion chemotherapy. TACE combined with anti-angiogenesis therapy may improve tumor control and prolong progression free survival. The combination therapy of TACE and immunotherapy may improve the clinical efficacy of HCC. In future research, more basic and clinical studies are needed to explore the immunogenic intervention therapy.
摘要
本文讨论了谭所撰写的文章。经动脉化疗栓塞术（TACE）是晚期肝细胞癌（HCC）的主要治疗方法之一。还有其他血管介入治疗方法，包括载药微球TACE、经动脉放射性栓塞术和肝动脉灌注化疗。TACE联合抗血管生成治疗可能会改善肿瘤控制并延长无进展生存期。TACE与免疫治疗的联合疗法可能会提高HCC的临床疗效。在未来的研究中，需要更多的基础和临床研究来探索免疫原性干预疗法。
相似文献
1
Landscape of transarterial chemoembolization represented interventional therapy for hepatocellular carcinoma.经动脉化疗栓塞的概况代表了肝细胞癌的介入治疗。
World J Gastrointest Surg. 2024 Dec 27;16(12):3903-3906. doi: 10.4240/wjgs.v16.i12.3903.
2
The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review.经动脉化疗栓塞/肝动脉灌注化疗联合乐伐替尼及PD-1抑制剂治疗门静脉癌栓型肝细胞癌的疗效：一项系统评价
Front Oncol. 2023 Mar 9;13:1054072. doi: 10.3389/fonc.2023.1054072. eCollection 2023.
3
Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma.传统经动脉化疗栓塞术与载药微球经动脉化疗栓塞术：治疗不可切除肝细胞癌的更佳选择。
J Interv Med. 2020 Nov 10;4(1):11-14. doi: 10.1016/j.jimed.2020.10.006. eCollection 2021 Feb.
4
Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy.经动脉化疗栓塞和经动脉放射性栓塞在晚期肝细胞癌下行肝切除术中的疗效与安全性分析
World J Gastrointest Surg. 2023 Apr 27;15(4):687-697. doi: 10.4240/wjgs.v15.i4.687.
5
Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus Y-radioembolization for hepatocellular carcinoma.荟萃分析：药物洗脱微球经动脉化疗栓塞术与钇90放射性栓塞术治疗肝细胞癌的调整间接比较
Eur Radiol. 2017 May;27(5):2031-2041. doi: 10.1007/s00330-016-4548-3. Epub 2016 Aug 25.
6
Current research status of transarterial therapies for hepatocellular carcinoma.肝细胞癌经动脉治疗的当前研究现状
World J Gastrointest Oncol. 2024 Sep 15;16(9):3752-3760. doi: 10.4251/wjgo.v16.i9.3752.
7
Multifocal hepatocellular carcinoma: a narrative review assessing treatment options from the interventional radiologist's perspective.多灶性肝细胞癌：一篇从介入放射科医生角度评估治疗选择的叙述性综述
Ann Palliat Med. 2023 Nov;12(6):1244-1259. doi: 10.21037/apm-23-294. Epub 2023 Aug 9.
8
Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.载药微球栓塞化疗与常规肝动脉化疗栓塞治疗肝细胞癌疗效及生存的综合预测因素
Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101460. doi: 10.1016/j.clinre.2020.05.008. Epub 2020 Jun 24.
9
Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.适合经动脉栓塞术的肝细胞癌患者的经动脉治疗：一项美国成本效益分析。
J Med Econ. 2023 Jan-Dec;26(1):1061-1071. doi: 10.1080/13696998.2023.2248840.
10
The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.药物洗脱微球（与常规相比）经动脉化疗栓塞治疗中晚期肝细胞癌对肝纤维化的影响。
Cancer Biol Ther. 2023 Dec 31;24(1):2166335. doi: 10.1080/15384047.2023.2166335.
本文引用的文献
1
Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma.经动脉化疗栓塞联合替雷利珠单抗治疗不可切除肝细胞癌患者
World J Gastrointest Surg. 2024 Sep 27;16(9):2829-2841. doi: 10.4240/wjgs.v16.i9.2829.
2
A study comparing the cost-effectiveness of conventional and drug-eluting transarterial chemoembolisation (cTACE and DEB-TACE) for the treatment of hepatocellular carcinoma in an Australian public hospital.一项比较传统和药物洗脱经动脉化疗栓塞术（cTACE 和 DEB-TACE）治疗澳大利亚公立医院肝细胞癌的成本效益的研究。
J Med Imaging Radiat Oncol. 2024 Sep;68(6):714-720. doi: 10.1111/1754-9485.13731. Epub 2024 Jul 10.
3
Hepatocellular carcinoma.肝细胞癌。
Eur J Surg Oncol. 2024 Jan;50(1):107313. doi: 10.1016/j.ejso.2023.107313. Epub 2023 Dec 6.
4
Efficacy and safety of lenvatinib-transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study.仑伐替尼经导管动脉化疗栓塞序贯治疗联合手术切除治疗超 UCSF 标准 7 分的中期肝细胞癌的疗效和安全性：一项多中心、单臂、前瞻性研究的研究方案。
BMJ Open. 2023 Oct 5;13(10):e073797. doi: 10.1136/bmjopen-2023-073797.
5
Efficacy of sequential TACE on primary hepatocellular carcinoma with microvascular invasion after radical resection: a systematic review and meta-analysis.序贯 TACE 治疗原发性肝癌伴微血管侵犯根治性切除术后的疗效：系统评价和荟萃分析。
World J Surg Oncol. 2023 Sep 5;21(1):277. doi: 10.1186/s12957-023-03160-0.
6
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice.免疫检查点抑制剂在肝细胞癌中的应用：临床实践中的新挑战。
Lancet Gastroenterol Hepatol. 2023 Aug;8(8):760-770. doi: 10.1016/S2468-1253(23)00147-4. Epub 2023 Jun 14.
7
TREM2 macrophages suppress CD8 T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma.TREM2 巨噬细胞抑制肝癌经动脉化疗栓塞术后 CD8+T 细胞浸润。
J Hepatol. 2023 Jul;79(1):126-140. doi: 10.1016/j.jhep.2023.02.032. Epub 2023 Mar 6.
8
Management of Hepatocellular Carcinoma: A Review.肝细胞癌的管理：综述
JAMA Surg. 2023 Apr 1;158(4):410-420. doi: 10.1001/jamasurg.2022.7989.
9
DEB-TACE with irinotecan C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study.伊立替康载药微球经动脉化疗栓塞术对比传统经动脉化疗栓塞术治疗不可切除性肝内胆管癌的前瞻性临床研究
Front Bioeng Biotechnol. 2023 Jan 12;10:1112500. doi: 10.3389/fbioe.2022.1112500. eCollection 2022.
10
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.PD-1/PD-L1 检查点抑制剂在晚期肝细胞癌免疫治疗中的应用。
Front Immunol. 2022 Dec 19;13:1070961. doi: 10.3389/fimmu.2022.1070961. eCollection 2022.
Zotero 插件